EP4130732A4 - Procédé d'analyse de molécules d'impuretés dans une composition contenant des molécules de liaison à un antigène multi-spécifiques - Google Patents

Procédé d'analyse de molécules d'impuretés dans une composition contenant des molécules de liaison à un antigène multi-spécifiques Download PDF

Info

Publication number
EP4130732A4
EP4130732A4 EP21780596.9A EP21780596A EP4130732A4 EP 4130732 A4 EP4130732 A4 EP 4130732A4 EP 21780596 A EP21780596 A EP 21780596A EP 4130732 A4 EP4130732 A4 EP 4130732A4
Authority
EP
European Patent Office
Prior art keywords
molecules
composition containing
analysis method
specific antigen
containing multi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21780596.9A
Other languages
German (de)
English (en)
Other versions
EP4130732A1 (fr
Inventor
Motohiko Sato
Hiroko Murata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP4130732A1 publication Critical patent/EP4130732A1/fr
Publication of EP4130732A4 publication Critical patent/EP4130732A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
EP21780596.9A 2020-04-02 2021-04-01 Procédé d'analyse de molécules d'impuretés dans une composition contenant des molécules de liaison à un antigène multi-spécifiques Pending EP4130732A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020066824 2020-04-02
PCT/JP2021/014120 WO2021201202A1 (fr) 2020-04-02 2021-04-01 Procédé d'analyse de molécules d'impuretés dans une composition contenant des molécules de liaison à un antigène multi-spécifiques

Publications (2)

Publication Number Publication Date
EP4130732A1 EP4130732A1 (fr) 2023-02-08
EP4130732A4 true EP4130732A4 (fr) 2024-06-19

Family

ID=77930432

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21780596.9A Pending EP4130732A4 (fr) 2020-04-02 2021-04-01 Procédé d'analyse de molécules d'impuretés dans une composition contenant des molécules de liaison à un antigène multi-spécifiques

Country Status (5)

Country Link
US (1) US20240183826A9 (fr)
EP (1) EP4130732A4 (fr)
JP (1) JPWO2021201202A1 (fr)
CN (1) CN115380210A (fr)
WO (1) WO2021201202A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102168733B1 (ko) 2011-10-31 2020-10-23 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291703A1 (en) * 2012-11-05 2015-10-15 Zenyaku Kogyo Kabushikikaisha Antibody and antibody composition production method

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2385347C (fr) 1999-10-04 2009-12-15 Medicago Inc. Methode de regulation de la transcription des genes etrangers
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DK2009101T3 (en) * 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
US10005839B2 (en) * 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
WO2017117384A1 (fr) * 2015-12-31 2017-07-06 Development Center For Biotechnology Anticorps anti-vegfr et utilisations associées
CN107525934A (zh) * 2016-06-21 2017-12-29 张效龙 一种测定血液中抗体氨基酸序列的方法
BR112019004901A2 (pt) * 2016-09-13 2019-06-25 E&S Healthcare Co Ltd anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, seu método de preparação, molécula de ácido nucleico, vetor recombinante, célula hospedeira, kit de diagnóstico e método para fornecer informações

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291703A1 (en) * 2012-11-05 2015-10-15 Zenyaku Kogyo Kabushikikaisha Antibody and antibody composition production method

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Bacterial Pathogenesis", vol. 1535, 3 December 2016, NEW YORK, NY : HUMANA PRESS, [2017], US, ISBN: 978-1-4939-6671-4, article JONATHAN SJÖGREN: "Generating and Purifying Fab Fragments from Human and Mouse IgG Using the Bacterial Enzymes IdeS, SpeB and Kgp", pages: 319 - 329, XP055614869, DOI: 10.1007/978-1-4939-6673-8_21 *
AMARAL MARTA ET AL: "Engineered Technologies and Bioanalysis of multispecific Antibody Formats", JOURNAL OF APPLIED BIOANALYSIS, vol. 6, no. 1, 31 January 2020 (2020-01-31), pages 26 - 51, XP055822537, Retrieved from the Internet <URL:https://betasciencepress-publishing.com/wp-content/uploads/1017145_jab_pdf/JAB20005-Engineered-Technologies-and-Bioanalysis-of-multispecific-Antibody-Formats.pdf> DOI: 10.17145/jab.20.005 *
CHUNLEI WANG ET AL: "A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture", MABS, vol. 10, no. 8, 20 September 2018 (2018-09-20), US, pages 1226 - 1235, XP055723596, ISSN: 1942-0862, DOI: 10.1080/19420862.2018.1511198 *
PHUNG WILSON ET AL: "Characterization of bispecific and mispaired IgGs by native charge-variant mass spectrometry", INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, ELSEVIER SCIENCE PUBLISHERS , AMSTERDAM, NL, vol. 446, 12 September 2019 (2019-09-12), XP085878606, ISSN: 1387-3806, [retrieved on 20190912], DOI: 10.1016/J.IJMS.2019.116229 *
See also references of WO2021201202A1 *
YIYUAN YIN ET AL: "Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry", MABS, vol. 8, no. 8, 9 September 2016 (2016-09-09), US, pages 1467 - 1476, XP055571287, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1232217 *

Also Published As

Publication number Publication date
EP4130732A1 (fr) 2023-02-08
CN115380210A (zh) 2022-11-22
US20230152280A1 (en) 2023-05-18
WO2021201202A1 (fr) 2021-10-07
US20240183826A9 (en) 2024-06-06
JPWO2021201202A1 (fr) 2021-10-07

Similar Documents

Publication Publication Date Title
EP4130732A4 (fr) Procédé d&#39;analyse de molécules d&#39;impuretés dans une composition contenant des molécules de liaison à un antigène multi-spécifiques
WO2011106693A3 (fr) Western blot à micro-échelle
EP4227949A4 (fr) Procédé de prédiction de rétrosynthèse pour molécule de composé, et appareil associé
EP4126970A4 (fr) Procédé de production de molécules multispécifiques de liaison à un antigène
EA201001395A1 (ru) Специфичные примеси монтелукаста
EP3611502A4 (fr) Procédé d&#39;injection d&#39;échantillon d&#39;enrichissement de micro-colonne
EP4067366A4 (fr) Procédé de purification de la progestérone
EP4039796A4 (fr) Procédé de production de composition pour la culture cellulaire, composition pour la culture cellulaire obtenue par ce dernier, et procédé de culture cellulaire l&#39;utilisant
BR112014004119A2 (pt) método e dispositivo para produção de cerveja
EP4064194A4 (fr) Procédé d&#39;analyse de levures
EP4034671A4 (fr) Composition et procédé pour améliorer la détection de biomolécules dans des échantillons de fluides biologiques
EP3859346A4 (fr) Procédé d&#39;introduction d&#39;un échantillon dans un dispositif de traitement d&#39;échantillon
EP4148018A4 (fr) Méthode de concentration d&#39;astate simple
EP4053549A4 (fr) Procédé de détermination de la structure d&#39;une substance dans un échantillon multicomposant
EP4026856A4 (fr) Procédé de fabrication de perfluoroélastomère, et composition
EP3980068A4 (fr) Procédés de culture cellulaire et compositions pour la production d&#39;anticorps
EP3701018A4 (fr) Compositions, procédés et kits pour la digestion en une étape d&#39;acide nucléique pour analyse par chromatographie en phase liquide-spectrométrie de masse en tandem
EP4100513A4 (fr) Procédés d&#39;amélioration de lymphocytes t par vénétoclax
EP4132505A4 (fr) Méthodes pour traiter le diabète
EP3936870A4 (fr) Méthode de quantification de her2 dans un échantillon de cancer du sein par spectrométrie de masse et méthode de notation de l&#39;état her2 l&#39;utilisant
EP4028058A4 (fr) Compositions et procédés de production et d&#39;utilisation d&#39;anticorps multispécifiques
EP3820989A4 (fr) Appareil de surveillance de molécules de gaz dans des procédés basés sur la fermentation
EP3919396A4 (fr) Procédé de fabrication de bouteille contenant un liquide de contenu
EP3742152A4 (fr) Dispositif d&#39;analyse spectroscopique, procédé d&#39;analyse spectroscopique, procédé de fabrication de feuillard et procédé d&#39;assurance qualité pour feuillard
EP3730611A4 (fr) Procédé de quantification du nombre de cellules d&#39;une bactérie dans un échantillon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: G01N0030020000

Ipc: G01N0030880000

A4 Supplementary search report drawn up and despatched

Effective date: 20240517

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/08 20060101ALI20240513BHEP

Ipc: C12N 15/13 20060101ALI20240513BHEP

Ipc: C07K 16/06 20060101ALI20240513BHEP

Ipc: C07K 16/36 20060101ALI20240513BHEP

Ipc: C07K 16/30 20060101ALI20240513BHEP

Ipc: C07K 16/28 20060101ALI20240513BHEP

Ipc: C07K 16/22 20060101ALI20240513BHEP

Ipc: C07K 16/46 20060101ALI20240513BHEP

Ipc: G01N 30/96 20060101ALI20240513BHEP

Ipc: G01N 30/89 20060101ALI20240513BHEP

Ipc: G01N 30/88 20060101AFI20240513BHEP